LOADING…
SPECIFICATIONS
01 / Metabolic / SMG-5
GLP-1 receptor agonist. 5 mg lyophilized vial.
DOSE
QUANTITY
BUNDLE & SAVE
SHIPS
FRI · 2-5 BIZ DAYS
PAY WITH
USDC · SOLANA
REFERENCE
COMPOUND DATA AND PEER-REVIEWED CITATIONS FOR SEMAGLUTIDE. FOR RESEARCH USE ONLY.
COMPOUND INFORMATION · TECHNICAL SPECIFICATIONS
MOLECULAR PROFILE
SYNONYMS
STORAGE REQUIREMENTS
LYOPHILIZED (POWDER)
-20°C · up to 2 years
RECONSTITUTED
2-8°C · up to 30 days
SOURCES & REFERENCES · PEER-REVIEWED RESEARCH · 8 CITATIONS FOR SEMAGLUTIDE
LANCET (LONDON, ENGLAND)
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
2021 · PMID 33667417
Davies M, Færch L et al.
VIEW SOURCE →
FRONTIERS IN ENDOCRINOLOGY
Safety of Semaglutide.
2021 · PMID 34305810
Smits MM, Van Raalte DH
VIEW SOURCE →
JOURNAL OF THE ASEAN FEDERATION OF ENDOCRINE SOCIETIES
IMPORTANT RESEARCH NOTICE
NOT FOR HUMAN CONSUMPTION. THIS PRODUCT IS SOLD EXCLUSIVELY FOR RESEARCH AND EDUCATIONAL PURPOSES. IT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.
ALL CITATIONS ON THIS PAGE ARE SOURCED FROM PUBMED AND PUBCHEM PUBLIC DATABASES. THEY ARE PROVIDED FOR EDUCATIONAL REFERENCE ONLY AND SHOULD NOT BE INTERPRETED AS MEDICAL ADVICE OR PRODUCT CLAIMS.
BY PURCHASING THIS PRODUCT, YOU CONFIRM THAT YOU ARE A QUALIFIED RESEARCHER AND WILL USE IT IN ACCORDANCE WITH ALL APPLICABLE LAWS.
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
2022 · PMID 36578889
Tan HC, Dampil OA et al.
VIEW SOURCE →